Assessing the Use of MY-RIDE, a Just-in-time Adaptive Intervention, to Improve HIV Prevention and Substance Use in Youth Experiencing Homelessness
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jennifer Jones
- Phone Number: 713-500-9928
- Email: Jennifer.D.Torres@uth.tmc.edu
Study Contact Backup
- Name: Diane M Santa Maria, DrPH, MSN, RN, PHNA-BC, FSAHM
- Phone Number: 713-500-2002
- Email: Diane.M.SantaMaria@uth.tmc.edu
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas Health Science Center at Houston
-
Contact:
- Jennifer Jones
- Phone Number: 713-500-9928
- Email: Jennifer.D.Torres@uth.tmc.edu
-
Contact:
- Diane M Santa Maria, DrPH, MSN, RN, PHNA-BC, FSAHM
- Phone Number: 713-500-2002
- Email: Diane.M.SantaMaria@uth.tmc.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- have engaged in substance use (alcohol or illicit drugs)
- speak English
- are experiencing homelessness
- engaged in sexual activity in the last 6 months or plan to in the next month
- are not planning to move out of the metro area during the 15-month study period.
Exclusion Criteria:
- Youth Experiencing Homelessness (YEH) who have low literacy based on the Rapid Estimate of Adult Literacy in Medicine-Short Form (scores < 4)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: MY-RIDE group
|
MY-RIDE has three main components: 1) One nurse-led face-to-face session; 2) three months of Ecological Momentary Assessments (EMA) with personalized messaging delivered by phone in real-time in response to one's current risk; and 3) access to on-demand healthcare/PrEP navigation and referrals.
|
|
Active Comparator: Attention-control group
|
Participants will receive a one-hour general health promotion session from a nurse and be issued a phone that will deploy the EMA on the same schedule as the intervention arm.
They will also receive usual care from the clinics, drop-in center, and shelter recruitment sites.
Usual care includes accessing social workers and case managers for immediate housing, food, and clothing needs and assistance in navigating the local Continuum of Care system to access social services.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in substance use
Time Frame: baseline, end of intervention (3 months after baseline), 3 months after intervention, 6 months after intervention, and 12 months after intervention
|
baseline, end of intervention (3 months after baseline), 3 months after intervention, 6 months after intervention, and 12 months after intervention
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in condom use
Time Frame: baseline, end of intervention (3 months after baseline), 3 months after intervention, 6 months after intervention, and 12 months after intervention
|
baseline, end of intervention (3 months after baseline), 3 months after intervention, 6 months after intervention, and 12 months after intervention
|
|
|
Change in PrEP uptake as assessed by the self reported tool
Time Frame: baseline, end of intervention (3 months after baseline), 3 months after intervention, 6 months after intervention, and 12 months after intervention
|
PrEP uptake is defined as the self initiation of HIV prevention medication
|
baseline, end of intervention (3 months after baseline), 3 months after intervention, 6 months after intervention, and 12 months after intervention
|
|
Change in sexually transmitted infections (STIs)
Time Frame: baseline, end of intervention (3 months after baseline), 3 months after intervention, 6 months after intervention, and 12 months after intervention
|
This will be assessed by a blood test to detect biomarkers for HIV and Syphilis, and urine test for Gonorrhea and Chlamydia
|
baseline, end of intervention (3 months after baseline), 3 months after intervention, 6 months after intervention, and 12 months after intervention
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Diane M Santa Maria, DrPH, MSN, RN, PHNA-BC, FSAHM, The University of Texas Health Science Center, Houston
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Blood-Borne Infections
- Urogenital Diseases
- Genital Diseases
- Immune System Diseases
- Infections
- RNA Virus Infections
- Virus Diseases
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- HIV Infections
Other Study ID Numbers
Other Study ID Numbers
- HSC-SN-23-0360
- 1R01NR020997-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.